Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease

NCT02337907 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02337907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02337907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
January 21, 2015
Completion date
October 10, 2017
Enrollment
329 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease